Split History
SRRA split history picture
SRRA (SRRA) has 1 split in our SRRA split history database. The split for SRRA took place on January 23, 2020. This was a 1 for 40 reverse split, meaning for each 40 shares of SRRA owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 25 share position following the split.

When a company such as SRRA conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the SRRA split history from start to finish, an original position size of 1000 shares would have turned into 25 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into SRRA shares, starting with a $10,000 purchase of SRRA, presented on a split-history-adjusted basis factoring in the complete SRRA split history. SRRA split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 01/11/2017
End date: 07/01/2022
Start price/share: $56.80
End price/share: $54.99
Dividends collected/share: $0.00
Total return: -3.19%
Average Annual Total Return: -0.59%
Starting investment: $10,000.00
Ending investment: $9,681.58
Years: 5.47
Sierra Oncology is a late-stage biopharmaceutical company focused on therapies that treat cancer. Co.'s focus is the development and commercialization of momelotinib, an investigational agent for the treatment of myelofibrosis. Momelotinib is a small-molecule inhibitor of JAK1 (Janus kinase 1), JAK2 (Janus kinase 2) and ACVR1 (Activin A receptor type 1), under development for treatment of patients with myelofibrosis. Co. has conducted a review of data from the two Phase 3 trials of momelotinib, versus ruxolitinib and best available therapy, as well as GS-US-352-1672, a Phase 2, open-label, translational biology trial of momelotinib in transfusion-dependent subjects with myelofibrosis. According to our SRRA split history records, SRRA has had 1 split.
Date Ratio
01/23/20201 for 40
SRRA is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

SSH Split History
SSKN Split History
STAA Split History
STE Split History
STEM Split History
STJ Split History
STXS Split History
SURG Split History
SYBX Split History
SYK Split History

Also explore: SRRA shares outstanding history

Email EnvelopeFree SRRA Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Crown Electrokinetics Corp. (CRKN)
Medalist Diversified REIT, Inc. (MDRR)
Medalist Diversified REIT, Inc. (MDRR)
Qilian International Holding Group Limited (QLI)
Bluejay Diagnostics, Inc. (BJDX)
Atara Biotherapeutics, Inc. (ATRA)
GRI Bio, Inc. (GRI)
Williams-Sonoma, Inc. (WSM)
Workhorse Group Inc. (WKHS)
Virgin Galactic Holdings, Inc. (SPCE)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

SRRA Insider Buying

SRRA Split History | www.SplitHistory.com | Copyright © 2013 - 2024, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
Wait! Don't leave yet.
Want to receive our latest research absolutely free?

Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.